Tiotropium Respimat is an inhaled corticosteroid drug patients administer once daily through Boehringer Ingelheim’s Respimat inhaler.
The FDA first approved the drug in 2015 for asthma patients age 12 and older. Now, the drug can also be used to treat children ages six and up.
More articles on supply chain:
4 thoughts from Trump’s CMS pick on reducing federal drug spending
Prime Therapeutics reports 2.5% increase in drug spending for 2016
FDA approves Valeant’s psoriasis drug
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
